Dopamine transporter (DAT) trafficking was assessed by functional measurements of dopamine uptake and by biotinylation of surface proteins followed by gel electrophoresis and Western blotting. In human embryonic kidney (HEK)-293 cells expressing human DAT (HEK-hDAT), pretreatment with dopamine (0.1-100 M) followed by washout caused reductions in subsequent dopamine uptake (reflected in V max ) with effective dopamine concentrations in the 10 to 100 M range and pretreatment times of 10 to 60 min. Reductions assessed after 60-min pretreatment with 100 M dopamine corresponded with decreases measured in surface DAT by the noncleavable biotin method, which were caused, at least in part, by enhanced endocytosis as monitored with cleavable biotin. Pretreatment of rat striatal synaptosomes with dopamine (10 and 100 M) also caused reductions in DAT uptake activity (V max ), and again the underlying mechanism seemed to be a diminished presence of DAT at the surface of synaptosomes as measured by the noncleavable biotin method. The copresence of cocaine during pretreatment with dopamine prevented the down-regulation of surface DAT. The present results show that DAT surface residency can be regulated by substrate acting on it, not only in cells heterologously expressing DAT but also in situ in rat brain tissue.In the brain, the dopamine transporter (DAT) clears extraneuronal dopamine, thereby terminating dopamine action (Iversen, 1971). It is generally thought that the local density of DAT is one factor that determines how much dopamine can be cleared, just as the density of dopamine receptors is crucial for the intensity of dopamine receptor-mediated signaling. In this context, many studies over the past decade have addressed long-term regulation of DAT density in chronic drug studies (for reviews, see Kuhar and Pilotte, 1996;Zahniser and Doolen, 2001). The idea that DAT is also susceptible to short-term regulation on a scale of minutes, through changes in its presence at the cell surface, is more recent and originates in studies searching for a link between transporter activity and phosphorylation states. Thus, depending on the mode of treatment, the protein kinase C (PKC) activator -phorbol 12-myristate 13-acetate (PMA) rapidly increases (Quick et al., 1997) or decreases (Beckman et al., 1999) surface-resident GABA transporter 1 (GAT1) in oocytes or primary hippocampal cultures. Down-regulation of GAT1 is probably the physiologically relevant effect of PKC activation (Robinson, 2002). In addition, phorbol esters down-regulate, or reduce surface activity, of monoamine transporters for serotonin (Qian et al., 1997), norepinephrine (Apparsundaram et al